Health Care Distributors(IN40221.SH)

Insilico Medicine and Qilu Pharmaceutical Sign Nearly $120 Million Drug Development Deal

Insilico Medicine and Qilu Pharmaceutical Group have entered a strategic partnership worth nearly $120 million to develop small molecule inhibitors for cardiometabolic diseases. Insilico will utilize its Pharma.AI platform for molecule design, while Qilu will manage development and commercialization. The agreement includes milestone payments and royalties based on net sales, aiming to enhance innovative therapy development through AI.

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi

Luye Pharma Group Ltd. has finalized the transfer of a 25% equity stake in its subsidiary, Nanjing Luye, to NJ Xinshi. As of January 19, 2026, Nanjing Luye is now 75% owned by Luye Pharma and 25% by NJ Xinshi. This partnership agreement ensures that Luye Pharma retains control over Nanjing Luye's governance and strategic objectives.

China National Accord Medicines Sees 2025 Net Profit Up 64.2-89.1%

China National Accord Medicines Corp Ltd :SEES 2025 NET PROFIT UP 64.2-89.1%

Pharmaceutical commercial stocks opened higher, with Yifeng Pharmacy hitting the daily limit, followed by DSL, Jointown, Hezong Medicine Easy-To-Buy Pharmaceutical, SYPM, and LBX. In terms of news, the Ministry of Commerce and 8 other departments issued the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry."